The Innovation Reduction Act with Allan Shaw
Business Of Biotech
00:00
The Future of Pharma and Biopharma
I'm curious what your thoughts are on, I guess, strategic response right right now. What should leaders of pharma and biopharma companies be doing to mitigate some of the fallout or take advantage of any silver linings in the act that they can? You know, it really depends where you sit, right? If you're a small molecule company, I think you're pregnant if you've got things in development, but I think it will potentially influence your programs who you might even partner with in the future. There's a lot of other factors at play.
Transcript
Play full episode
